profit from every $100 of sales.
$0$100
Onconetix
$3.03-19.41% today
-78.0% in 1 year
1-year low $3.031-year high $98.50
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Onconetix sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $815,371 in 2025, with -$14.0 million of profit last year.
SalesProfit
Onconetix vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Onconetix | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Onconetix's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 3 | 1 | |
| 0 | -1 | 1 | 1 | |
| -13 | -18 | -10 | -6 | |
| -13 | -37 | -58 | -13 | |
| -13 | -37 | -59 | -14 | |
| -151,867.29 | -285,570.18 | -21,301.06 | -828.00 | |
| – | -1,927.9% | 41.8% | 77.6% | |
| – | -30,526.4% | -409.3% | -778.2% | |
| – | -63,986.5% | -2,325.2% | -1,721.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 26 | 88 | 28 | 25 |
| Cash | 26 | 5 | 1 | 5 |
| Total debt | 0 | 10 | 9 | 0 |
| Total liabilities | 4 | 86 | 19 | 9 |
| 22 | -6 | 10 | 16 | |
| 0 | 0 | 0 | 0 | |
| -47.4% | -677.7% | -241.8% | -66.3% | |
| -59.9% | 667.8% | -610.7% | -89.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -9 | -14 | -10 | -10 | |
| 0 | 0 | 0 | – | |
| -9 | -14 | -11 | -10 | |
| Dividends paid | – | – | – | – |
| 1 | 0 | 0 | 2 | |
| 2 | 0 | 0 | 0 |
Valuation
- –
- –
- –
- 0.1×
- 2.5×
- –
- –
- -476.7%
- -691.2%
- 0.0%
Profitability
- 77.6%
- -778.2%
- -1,721.0%
- -2,480.4%
- -112.9%
- -313.2%
- -189.8%
- -56.3%
- -113.1%
- -2.1%
Growth
- +273.4%
- –
- +8.0%
- –
- +312.2%
Financial health
- -0.4×
- 0.00
- 0.2%
- -23.8×
- 0.66
- 0.65
- 0.03
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 1%of 870
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -6.71 | – | – |
| Mar 12, 2026 | 12.58 | – | – |
| Nov 13, 2025 | -6.25 | – | – |
| Aug 14, 2025 | -4.05 | – | – |
| Jun 12, 2025 | 21.19 | – | – |
| Apr 10, 2025 | -212.88 | – | – |
| Dec 9, 2024 | -189.83 | – | – |
| Aug 29, 2024 | -779.66 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
42No pass
Benjamin Graham
59No pass
Philip Fisher
58No pass
Peter Lynch
–Not enough data
Joel Greenblatt
0No pass
Charlie Munger
50No pass
Terry Smith
44No pass
Questions about Onconetix
Is Onconetix a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Onconetix AI analysis
What does Onconetix do?
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. It is in Biotechnology.
Does Onconetix pay a dividend?
No. Onconetix does not pay a dividend at the moment; in 2025 it returned $1.71 million to shareholders by buying back its own shares.
Is Onconetix stock halal?
No. Onconetix does not pass our halal screen: its cash and confirmed interest-bearing investments are 257% of its market value, at or above the 33% limit. How we check
How has Onconetix stock done over the past year?
Down 78.0% over the past twelve months, to $3.03. It traded between $3.03 and $98.50 and is 96.9% below its high.
Who are Onconetix's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Onconetix's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.